JOHNSON & JOHNSON
NYSE: JNJ·New Brunswick, New Jersey·CIK 0000200406
- Price
- $282.55
- Base IV
- $140.03
Valuation snapshot
At $282.55, the price is above even our bull case of $194.72.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $140.03
- 50% of the price · range $89.87–$194.72
- Price vs base case
- 102% above
- $282.55 against $140.03
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $89.87 to bull $194.72. Values per share.
Price against each value
- Bear case
- $89.87
- Price 214% above
- No growth
- …
- —
- Base case
- $140.03
- Price 102% above
What does Johnson & Johnson do?
Johnson & Johnson makes prescription medicines and medical devices that help doctors treat cancer, immune diseases, heart problems and brain disorders, and perform surgery.
It brought in $99.3B of sales in the 12 months to Sep 2026.
Led by Joaquin Duato, Chairman of the Board and Chief Executive Officer since 2022. Johnson & Johnson 2026 Proxy Statement (Form DEF 14A)
- Industry
- Healthcare
- Based in
- New Brunswick, New Jersey
- Trades on
- NYSE as JNJ
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 16¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 32¢ of every dollar.
- Making what it sells32¢
- Research and development16¢
- Sales, marketing and admin26¢
- Everything else, including interest8¢
- Tax2¢
- Left as profit16¢
Who pays Johnson & Johnson, and for what?
Johnson & Johnson makes prescription medicines and medical devices. Its larger segment, Innovative Medicine, sells drugs for cancer, immune diseases, mental health and other conditions. Its MedTech segment sells heart devices, surgical tools, orthopaedic implants and contact lenses. In 2025 it had $94.2 billion of sales, about 43% of them outside the U.S.
The company sells mainly to drug wholesalers, distributors, retailers, hospitals, clinics, doctors and eye care professionals, and much of the final bill is paid by insurers and government health programs such as Medicare.
Innovative Medicine
64%Prescription medicines for cancer (such as DARZALEX and CARVYKTI), immune diseases (TREMFYA, STELARA), brain and mental health (SPRAVATO, CAPLYTA), lung blood pressure, HIV, and heart and metabolism. DARZALEX alone was about 15% of total company sales in 2025.
MedTech
36%Medical devices: heart products (including Abiomed heart pumps and Shockwave), orthopaedic implants (DePuy Synthes), surgical tools (Ethicon), and vision products such as ACUVUE contact lenses and TECNIS lens implants.
Where its work physically happens, beyond headquarters:
- Wilson Biologics Manufacturing Campus — Wilson, United States. Two adjacent $2+ billion advanced-technology biologics plants that will expand production of J&J's monoclonal-antibody portfolio in oncology, immunology and neuroscience, supporting more than 70 planned filings/launches by decade's end.
- Janssen Sciences Ireland Biopharmaceutical Campus — Ringaskiddy, Cork, Ireland. A World Economic Forum 'Global Lighthouse' biologics supply-chain hub that has received hundreds of millions of euros in repeated expansions, underpinning ex-U.S. supply of J&J's biologic medicines.
- Janssen Beerse/Geel Campus — Beerse, Belgium. J&J's largest pharmaceutical R&D campus outside the U.S., spanning discovery-to-commercial-supply capabilities; the co-located Geel site alone produces roughly 60% of J&J's global active pharmaceutical ingredient capacity.
- J&J Vision (Vistakon) Jacksonville Campus — Jacksonville, United States. Manufactures roughly 90% of the U.S. supply of ACUVUE contact lenses (about 1.7 billion lenses/year), with a new $1 billion+ investment expanding manufacturing, packaging and distribution capacity through 2028.
- Raritan Cell Therapy Manufacturing Facility — Raritan, United States. The largest cell therapy manufacturing facility in the U.S., producing CARVYKTI (with partner Legend Biotech) with installed capacity for up to 10,000 patients annually, a key growth driver in J&J's oncology franchise.
Johnson & Johnson Form 10-K for fiscal 2025 (Item 1 Business)
How is the business doing?
Sales grew from $82.6B in 2020 to $94.2B in 2025, about 3% a year.
After paying for its upkeep and new investment, it had $20.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company says it exists to build a world where complex diseases are prevented, treated and cured, guided by its long-standing value statement, Our Credo.
“With Our Credo as the foundation, the Company believes health is everything.”
Who is responsible for the plan?
- Joaquin DuatoChairman of the Board and Chief Executive Officer
Leads Johnson & Johnson as CEO and chairs its Board of Directors and Executive Committee. As CEO he oversees both reporting segments, Innovative Medicine and MedTech, which generate the company's sales.
- Tom CavanaughExecutive Vice President, Worldwide Chairman, Innovative Medicine
Leads the Innovative Medicine business worldwide and sits on the Johnson & Johnson Executive Committee. Innovative Medicine sells prescription medicines and is the larger of J&J's two segments, with about $60.4 billion in 2025 sales.
John C. Reed, M.D., Ph.D.Executive Vice President, Innovative Medicine R&DLeads research and development for the Innovative Medicine pipeline. The R&D pipeline he leads produces the new medicines that the Innovative Medicine segment brings to market and sells.
Roles checked November 13, 2026.
What management says it is working on now:
Passing $100 billion in yearly sales
CEO Joaquin Duato said the company is on track to meet its 2026 target of more than $100 billion in yearly sales. It would be the first time in the company's 140-year history.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)Growing newer medicines to replace STELARA
Growth is led by cancer drugs such as DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT, plus TREMFYA and SPRAVATO. These are making up for falling STELARA sales. Products launched in the past five years were about 25% of 2025 sales.
Johnson & Johnson Form 10-K for fiscal 2025Separating the orthopaedics business
In October 2025 the company announced plans to separate its orthopaedics business into a standalone company called DePuy Synthes. It is aiming to finish within 18 to 24 months.
Johnson & Johnson Announces Intent to Separate Its Orthopaedics BusinessAdding to the pipeline through deals
After buying Intra-Cellular Therapies (maker of CAPLYTA) in 2025, the company agreed in the second quarter of 2026 to buy Firefly Bio to add a new type of cancer treatment technology.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)Expanding heart and surgery devices, and U.S. manufacturing
In MedTech, the company is pushing heart-rhythm and heart-pump products and launching new devices such as Shockwave C2 Aero. It is also investing more than $1 billion in a U.S. vision products plant in Jacksonville, Florida.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
- Reported sales, Full year 2026
- $100.8 billion to $101.4 billion (7.0% to 7.6% growth)
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
- Sales growth excluding currency effects and deals, Full year 2026
- 6.2% to 6.8%
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
- Adjusted earnings per share, Full year 2026
- $11.60 to $11.75 (7.5% to 8.9% growth)
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
- Orthopaedics business separation, Within 18 to 24 months of October 2025
- Completed
- Johnson & Johnson Form 10-K for fiscal 2025
What's changing right now?
Growth is slowing. In Q3 2026 it sold 6% more than a year earlier. The year before, quarters averaged 8%.
Since Sep 2026 the share price has risen 1%, from $278.43 to $282.55.
Recently
September 27, 2026
Innovative Medicine third-quarter sales changed to $16.8B
JNJ Q3 2026 resultsSeptember 27, 2026
Nine-month capital additions share changed to 5.0%
JNJ Q3 2026 Form 10-QFebruary 11, 2026
Annual core operating profit margin changed to 26.8%
JNJ 2025 Form 10-K
Coming up
Targeted within 18 to 24 months of October 2025 (about mid-2027)
Orthopaedics business separation
The company plans to separate DePuy Synthes, its orthopaedics business, into a standalone company. This would make Johnson & Johnson a smaller company more focused on medicines and higher-growth devices.
Johnson & Johnson Form 10-Q for the quarter ended June 28, 2026Pending; review granted in the second quarter of 2026
FDA decision on IMAAVY for a rare blood disorder
The FDA granted Priority Review, which means a faster review, to IMAAVY for warm autoimmune hemolytic anemia, a disease in which the immune system destroys red blood cells.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)2028
Government-set Medicare price for ERLEADA
The prostate cancer drug ERLEADA was added to the list of drugs whose Medicare price the government will set, which is likely to lower its U.S. sales.
Johnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)2029
DARZALEX U.S. patent expiry
The core U.S. patents on DARZALEX, about 15% of company sales in 2025, are set to expire. That could open the door to cheaper competing versions.
Johnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
Our own estimate moved too: the base case went from $152.60 to $140.03 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Talc lawsuits
The company faces many lawsuits claiming that talc body powders, mainly JOHNSON'S Baby Powder, caused harm, and some cases involve thousands of plaintiffs. It does not buy outside insurance for these claims, so large payouts would come from its own funds.
From the company's own filingsWould hit how much of each sale it keepsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
Cheaper copies of former best-sellers
STELARA sales fell 41.3% in 2025 as cheaper copycat versions launched, and the company expects further declines. It also expects copies of OPSUMIT in 2026 and says a copy of SIMPONI could cut its sales significantly.
From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025
Government drug price setting in the U.S.
Under the Inflation Reduction Act, Medicare prices set by the government for XARELTO, STELARA and IMBRUVICA began in 2026. ERLEADA will follow in 2028. The company is challenging the law in court.
From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
Patent expiries on key drugs
Competitors increasingly challenge its patents, and sales of a drug can drop quickly once its patents expire. The core U.S. patents on DARZALEX, its biggest product, expire in 2029, and TREMFYA's main U.S. patent is expected to expire in 2031.
From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
Tariffs and pricing pressure
U.S. tariffs, and the risk of other countries retaliating, can raise costs. The company said tariffs helped push MedTech profit margins down in the second quarter of 2026. Insurers, drug-benefit managers and discount programs also keep pushing prices lower.
From the company's own filingsWould hit how much of each sale it keepsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
Orthopaedics separation may not go as planned
The separation needs board, regulator and works council approvals. The company says it may not get the benefits it expects, and its share price may move more than usual around the separation.
From the company's own filingsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)
MedTech grew only 2.5% in Q3 2026 and missed estimates.
From our researchWould hit how fast sales growCNBC: J&J Q3 2026 earnings
2026 adjusted operational EPS guidance of $10.95-$11.05 is only about 2% growth on 7% sales growth, which points to margin pressure.
From our researchWould hit how much of each sale it keepsJ&J Q3 2026 prepared remarks
Is it a good business?
From 2017 to 2025 it earned between 2% and 51% on its shareholders' equity, a median of 25%.
The number of shares has held roughly steady over the past year.
It owes $27.4B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $282.55. Our put its value between $89.87 and $194.72, with $140.03 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $89.87
This scenario assumes J&J's recent pickup to about 6% sales growth fades to low single digits as the medical-device business stays sluggish and government drug-price cuts bite, while lawsuit costs keep profits below recent levels.
Base case, $140.03
This scenario assumes J&J keeps growing sales at around 5% a year for the next few years, close to its recent pace of about 6%, before slowly settling down, with profits holding near their usual high levels.
Bull case, $194.72
This scenario assumes J&J's new medicines keep sales growing at about 6-7% a year, similar to its best recent quarters, with profits edging higher as faster-growing drugs make up more of the business.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 102%
For Johnson & Johnson to be worth today's $282.55, sales would need to grow about 20.7% a year. We assume 4.5%. Over the last 5 years, sales grew 1.7% a year.
Or, if sales grow 4.5% as we assume, the price works with a profit margin of 62.2% (we assume 32.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 20.7% a year?
Try your own numbersWe're moderately sure of this range: it scores 63 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $140.03 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.5%
- Operating margin32.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$140.03 -50.4%


